Skip to main content
SpringerLink
Log in

Olodaterol: A Review of Its Use in Chronic Obstructive Pulmonary Disease

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Olodaterol (Striverdi® Respimat®) is an inhaled long-acting β2-adrenoceptor agonist (LABA) indicated as a once-daily maintenance bronchodilator therapy in adults with COPD. Several well-designed phase III trials have assessed use of the drug over 6 or 48 weeks in this patient population. In these studies, once-daily olodaterol improved lung function relative to placebo over 48 weeks of treatment, with such improvements being achieved and maintained within the 24-h dosage interval, supporting its once-daily administration. In addition, combined analyses of 48-week trials indicated that olodaterol reduces rescue medication use and may also improve dyspnoea and health-related quality of life, and crossover studies showed improvements in exercise endurance after 6 weeks of treatment with the drug. Pooled analyses of crossover studies assessing 24-h bronchodilation after 6 weeks of therapy indicated that once-daily olodaterol has a 24-h bronchodilatory profile generally similar to that of once-daily tiotropium bromide and twice-daily formoterol. Olodaterol was generally well tolerated and had an acceptable cardiovascular and respiratory adverse event profile. However, further longer-term and active comparator-controlled studies would be beneficial, including trials powered to assess COPD exacerbations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2015. http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html. Accessed 24 Feb 2015.

  2. World Health Organization. Chronic obstructive pulmonary disease (COPD): fact sheet no 315. 2015. http://www.who.int/mediacentre/factsheets/fs315/en/#. Accessed 24 Feb 2015.

  3. Guarascio AJ, Ray SM, Finch CK, et al. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013;5(1):235–45.

    PubMed Central  PubMed  Google Scholar 

  4. Boehringer Ingelheim International GmbH. Striverdi respimat (olodaterol) inhalation spray for oral inhalation: US prescribing information. 2014. http://www.accessdata.fda.gov. Accessed 24 Feb 2015.

  5. Boehringer Ingelheim International GmbH. Striverdi Respimat 2.5 microgram, solution for inhalation: EU summary of product characteristics. 2013. http://mri.medagencies.org/Human. Accessed 24 Feb 2015.

  6. Bouyssou T, Casarosa P, Naline E, et al. Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther. 2010;334(1):53–62.

    Article  CAS  PubMed  Google Scholar 

  7. Casarosa P, Kollak I, Kiechle T, et al. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol. J Pharmacol Exp Ther. 2011;337(3):600–9.

    Article  CAS  PubMed  Google Scholar 

  8. Feldman GJ, Bernstein JA, Hamilton A, et al. The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studies. Springerplus. 2014;3:419.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Lange P, Aumann J-L, Hamilton A, et al. The 24 hour lung function time profile of olodaterol once daily versus placebo and tiotropium in patients with moderate to very severe chronic obstructive pulmonary disease. J Pulm Resp Med. 2014;4(4). doi:10.4172/2161-105X.1000196.

  10. Ferguson GT, Feldman GJ, Hofbauer P, et al. Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9:629–45.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Koch A, Pizzichini E, Hamilton A, et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9:697–714.

    Article  PubMed Central  PubMed  Google Scholar 

  12. van Noord JA, Smeets JJ, Drenth BM, et al. 24-hour bronchodilation following a single dose of the novel β2-agonist olodaterol in COPD. Pulm Pharmacol Ther. 2011;24(6):666–72.

    Article  PubMed  Google Scholar 

  13. van Noord JA, Korducki L, Hamilton AL. Four weeks once daily treatment with BI 1744 CL, a novel long-acting beta-2- agonist, is effective in COPD patients [abstract no. 210]. Am J Resp Crit Care Med. 2009;179:A6183.

    Google Scholar 

  14. Ichinose M, Takizawa A, Izumoto T, et al. Efficacy of 4 weeks’ once-daily treatment with olodaterol (BI 1744), a novel long-acting B2-agonist, in Japanese patients with COPD [abstract no. A2931]. Am J Respir Crit Care Med. 2012;185 (meeting abstracts).

  15. Joos G, Aumann JL, Coeck C, et al. Comparison of 24-hour FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting B2-agonist, in patients with COPD [abstract no. A2930]. Am J Respir Crit Care Med. 2012;185 (meeting abstracts).

  16. Brown SM, Barnes PJ, Donnelly LE. Effect of olodaterol on the relaxation of small airways [abstract]. In: Annual Congress of the European Respiratory Society; 2011.

  17. Troost J, Pivovarova A, Kunz C. Evaluation of the effects of the long-acting beta2-agonist olodaterol on the Qt and Qtc interval in healthy subjects [abstract no. B24]. Am J Resp Crit Care Med. 2013;187:A2603.

    Google Scholar 

  18. Maltais F, Kirsten A-M, Hamilton AL, et al. Evaluation of the effects of olodaterol on exercise endurance in patients with COPD: results from two 6-week studies [abstract]. Chest. 2013;144(4_meeting abstracts):748A.

  19. Ferguson G, Sachs P, Hamilton A, et al. Efficacy of olodaterol once daily (QD) via Respimat in GOLD 2/3 COPD patients not receiving background therapy: pooled data from 48-week studies [abstract]. Chest. 2013;144(4_meetingabstracts):727A.

  20. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85(6):751–8.

    Article  CAS  PubMed  Google Scholar 

  21. Niewoehner D, McGarvey L, Hamilton AL, et al. Pooled safety analysis of olodaterol once daily via Respimat® versus placebo and formoterol twice daily in patients with COPD: independently adjudicated respiratory-related serious adverse events [abstract]. Chest. 2013;144(4_meeting abstracts):712A.

  22. McGarvey L, Niewoehner D, Magder S, et al. One-year safety of olodaterol once daily via Respimat® in patients with GOLD 2–4 chronic obstructive pulmonary disease: results of a pre-specified pooled analysis. COPD. 2015. doi:10.3109/15412555.2014.991864.

  23. Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105(3):435–41.

    Article  PubMed  Google Scholar 

  24. Chung VC, Ma PH, Hui DS, et al. Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis. PLoS One. 2013;8(8):e70784.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Roskell NS, Anzueto A, Hamilton A, et al. Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol. Int J COPD. 2014;9:813–24.

    Article  CAS  Google Scholar 

  26. Buhl R, Derom E, Ferguson G, et al. Once-daily tiotropium and olodaterol fixed-dose combination via the respimat improves outcomes vs mono-components in COPD in two 1-year studies [abstract no. 1895]. In: 24th Annual Congress of the European Respiratory Society; 2014.

Download references

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered the opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit. Emma Deeks is a salaried employee of Adis/Springer.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Emma D. Deeks

Authors
  1. Emma D. Deeks
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emma D. Deeks.

Additional information

Manuscript reviewed by: S. A. Antoniu, University of Medicine and Pharmacy, Grigore T. Popa, Iasi, Romania; A. D. D’Urzo, Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada; A. F. Gelb, Geffen School of Medicine at the University of California Los Angeles Medical Center, Los Angeles, CA, USA and Pulmonary Division, Department of Medicine, Lakewood Regional Medical Center, Lakewood, CA, USA; C. Incorvaia, Pulmonary Rehabilitation Unit, ICP Hospital, Milan, Italy; E. M. Kerwin, Clinical Research Institute of Southern Oregon, Medford, OR, USA; D. M. Mannino, Department of Preventive Medicine, University of Kentucky College of Public Health, Lexington, KY, USA.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Deeks, E.D. Olodaterol: A Review of Its Use in Chronic Obstructive Pulmonary Disease. Drugs 75, 665–673 (2015). https://doi.org/10.1007/s40265-015-0371-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-015-0371-4

Keywords

Search

Navigation